Navigation Links
ShangPharma Announces Second Quarter 2011 Results
Date:8/22/2011

company related professional fees.

The build-up of corporate managerial and supporting infrastructure was near completion at the end of 2010.  The management team believes that the current infrastructure will be sufficient to support the future growth of the Company in the coming years.

Profit from operations was $2.8 million, a decrease of 12.7% from $3.2 million in the second quarter of 2010, primarily due to additional headcount resulting from a build-up of corporate managerial and supporting infrastructure in the second half of 2010, higher share-based compensation expenses and listed company related professional fees.  The decline was partially offset by the increase in gross profit.  

Non-GAAP profit from operations was $4.2 million, an increase of 22.2% from $3.4 million in the second quarter of 2010.  The rise was primarily due to higher gross profit and was partially offset by additional headcount resulting from a build-up of corporate managerial and supporting infrastructure in the second half of 2010 and listed company related professional fees.

Operating margin was 10.3%, compared with 14.8% in the second quarter of 2010.  The operational efficiency improvements were primarily offset by higher share-based compensation expenses and the continued appreciation of the Renminbi.

Non-GAAP operating margin was 15.2%, compared with 15.7% in the second quarter of 2010.  The decline was primarily due to continued Renminbi appreciation and listed company related professional fees, which was partially offset by the operational efficiency improvements.

Net income decreased 19.0% year-over-year to $3.4 million, primarily due to lower profit from operations and lower other income, including lower government subsidies and a smaller gain recognized on foreign exchange forward contracts.

Non-GAAP net income was $4.7 million, an increase of 9.0% from $4.3 million in the s
'/>"/>

SOURCE ShangPharma Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. ShangPharma Corporation Named a Top Ten Chinese Outsourcing Enterprise
2. ShangPharma Announces First Quarter 2011 Results
3. ShangPharma Corp. to Announce Fourth Quarter and Full Year 2010 Financial Results on March 15, 2011
4. Stem Cell Assurance, Inc. Announces Change of Name to BioRestorative Therapies, Inc.
5. Syndax Pharmaceuticals Announces Issuance of EU Patent for Entinostat
6. Regeneron Announces Review of Biologics License Application for EYLEA™ (aflibercept injection) Extended by Three Months by FDA
7. ACMG Announces New Online Live Learning Center: Will Bring Genetics and Genomics Education to Varied Health Professionals
8. Neurologix Announces Second Quarter 2011 Financial Results
9. Bion Announces New U.S. Patent for Phosphorus Removal
10. ViaCyte Announces Executive Management Changes
11. NeoStem Announces the Receipt of Over $1,700,000 in DOD Funding for its VSEL™ Technology Being Developed to Treat Osteoporosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... Communications, a leading provider of strategic communications services to corporations and ... the United States and Europe ... JD, is returning to the firm,s Washington, D.C. ... more than two years of service as Associate Commissioner for the ...
(Date:1/14/2014)... BETHESDA, Md. , Jan. 14, 2014  Organovo announced ... from the National Institutes of Health (NIH) to help ... effective treatments to patients on a faster timeline. Organovo ... Sciences (NCATS) and the National Eye Institute (NEI) to ...
(Date:1/14/2014)... MD (PRWEB) January 14, 2014 ... to developing innovative information technology solutions for patients, ... health care stakeholders, announced today the signing of ... US Food and Drug Administration (FDA). This ...
(Date:1/14/2014)... During the 1600’s through the 1800’s doctors contributed unknowingly ... this time period, doctors did not know that they needed ... death of vulnerable patients. In the same way, medical interns ... unwittingly transmitting herpes viruses to their patients. The CBCD explains. ...
Breaking Biology Technology:Former FDA Associate Commissioner Returns To 3D Communications 2Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 3
... , LONDON, Sept. 8 ... services to pharmaceutical and biotechnology companies, is pleased to announce ... office. Walter Colasante, as a Vice President, and Sophie ... and reimbursement expertise and expand its current offerings. , ...
... Sept. 8 PDL BioPharma, Inc. (PDL) (Nasdaq: ... ended September 30, 2009 of approximately $71 million, as compared ... revenues are based on second quarter product sales by PDL,s ... by MedImmune. When compared with 2008, royalty revenue for foreign ...
... PAREXEL International Corporation (Nasdaq: PRXL ) announced today it ... Boston, MA. Josef von Rickenbach, Chairman and Chief Executive Officer, ... EDT on Friday, September 11, 2009. , , ... "Upcoming Events" section on PAREXEL,s "Investors" homepage at www.PAREXEL.com ...
Cached Biology Technology:PriceSpective Appoints Colasante as a Vice President and Murdoch as a Director 2PDL BioPharma Provides Third Quarter 2009 Revenue Guidance of Approximately $71 Million 2PDL BioPharma Provides Third Quarter 2009 Revenue Guidance of Approximately $71 Million 3PAREXEL International to Present at Thomas Weisel Partners Healthcare Conference 2
(Date:7/9/2014)... fungal pathogens pose a greater threat to biodiversity ... of amphibians, bats, corals, bees and snakes. New ... in the prestigious journal Nature reveals ... to a deadly chytrid fungus implicated in global ... important because it is the basis of vaccination ...
(Date:7/9/2014)... from The Cancer Genome Atlas (TCGA) Research Network ... pathway in lung adenocarcinoma, the most common subtype ... may expand the number of possible therapeutic targets ... number of patients with treatable mutations because many ... exist. , TCGA is jointly funded and managed ...
(Date:7/9/2014)... be able to cope with the rising salinity of Arctic ... today is best known for its tundra and polar bear ... 38 million years ago during what is known as the ... temperate forest with brackish water, home to a variety of ... giant tortoises. Much of what is known about the region ...
Breaking Biology News(10 mins):USF study: Amphibians can acquire resistance to deadly fungus 2Study identifies novel genomic changes in the most common type of lung cancer 2Study identifies novel genomic changes in the most common type of lung cancer 3Shark teeth analysis provides detailed new look at Arctic climate change 2Shark teeth analysis provides detailed new look at Arctic climate change 3
... of the Lawson Health Research Institute and Professor of ... of Medicine & Dentistry at The University of Western ... biology from rebro University in Sweden. Dr. ... and the only recipient this year in the field ...
... of a seething, breathing microbial world. Microorganisms populate every ... of the human skin, to rainforest floors, to hydrothermal ... powerful and pervasive role of microbes in sustaining life, ... is the subject of The Uncharted Microbial World: Microbes ...
... twins are not genetically identical. This surprising finding ... a study being published today in the prestigious journal ... be of great significance for research on hereditary diseases ... How can it be that one identical twin might ...
Cached Biology News:Unexplored microbes hold incredible potential for science and industry 2Unexplored microbes hold incredible potential for science and industry 3
... is a new product number, created ... If showing no availability yet, please ... (E6152) or contact customer service for ... diam. 11.25 6.40 in. ...
... Analysis of large numbers of samples may ... which requires minimum operator attention. System control ... and interface CE 4900. The elegant, powerful ... Windows XP and Windows 98 and 2000., The ...
Mouse monoclonal antibody to QPCT - glutaminyl-peptide cyclotransferase (glutaminyl cyclase)...
... number is a new ... easily match Cornings product ... availability yet, please order ... number (Z35,347-7) or contact ...
Biology Products: